Verona Pharma PLC ADR (VRNA) - Net Assets
Based on the latest financial reports, Verona Pharma PLC ADR (VRNA) has net assets worth $278.27 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($572.87 Million) and total liabilities ($294.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore VRNA cash generation efficiency to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $278.27 Million |
| % of Total Assets | 48.58% |
| Annual Growth Rate | 28.74% |
| 5-Year Change | 10.66% |
| 10-Year Change | 2371.52% |
| Growth Volatility | 167.44 |
Verona Pharma PLC ADR - Net Assets Trend (2005–2024)
This chart illustrates how Verona Pharma PLC ADR's net assets have evolved over time, based on quarterly financial data. For live valuation and market cap data, see Verona Pharma PLC ADR market cap and net worth.
Annual Net Assets for Verona Pharma PLC ADR (2005–2024)
The table below shows the annual net assets of Verona Pharma PLC ADR from 2005 to 2024. Read Verona Pharma PLC ADR total liabilities for a breakdown of total debt and financial obligations.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $204.56 Million | -17.94% |
| 2023-12-31 | $249.28 Million | +8.16% |
| 2022-12-31 | $230.47 Million | +55.72% |
| 2021-12-31 | $148.00 Million | -19.93% |
| 2020-12-31 | $184.85 Million | +316.31% |
| 2019-12-31 | $44.40 Million | -44.40% |
| 2018-12-31 | $79.86 Million | -26.02% |
| 2017-12-31 | $107.95 Million | +153.84% |
| 2016-12-31 | $42.53 Million | +413.82% |
| 2015-12-31 | $8.28 Million | -57.81% |
| 2014-12-31 | $19.62 Million | +475.30% |
| 2013-12-31 | $3.41 Million | -18.95% |
| 2012-12-31 | $4.21 Million | -33.11% |
| 2011-12-31 | $6.29 Million | +18.09% |
| 2010-12-31 | $5.33 Million | -26.51% |
| 2009-12-31 | $7.25 Million | +23.91% |
| 2008-12-31 | $5.85 Million | +2.12% |
| 2007-12-31 | $5.73 Million | -25.01% |
| 2006-12-31 | $7.64 Million | +353.35% |
| 2005-12-31 | $1.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Verona Pharma PLC ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1257199.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $43.36 Million | 21.20% |
| Other Comprehensive Income | $-4.60 Million | -2.25% |
| Other Components | $728.20 Million | 355.98% |
| Total Equity | $204.56 Million | 100.00% |
Verona Pharma PLC ADR Competitors by Market Cap
The table below lists competitors of Verona Pharma PLC ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Andritz AG
VI:ANDR
|
$7.32 Billion |
|
Copenhagen Airports AS
CO:KBHL
|
$7.32 Billion |
|
Janus Henderson Group PLC
NYSE:JHG
|
$7.33 Billion |
|
Cencosud
SN:CENCOSUD
|
$7.33 Billion |
|
BARRY CALLEBA. ADR 1/100
F:BCLM
|
$7.31 Billion |
|
Applied Digital Corporation
NASDAQ:APLD
|
$7.31 Billion |
|
WIN Semiconductors
TWO:3105
|
$7.31 Billion |
|
Leo Group Co Ltd
SHE:002131
|
$7.30 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Verona Pharma PLC ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 249,283,000 to 204,559,000, a change of -44,724,000 (-17.9%).
- Net loss of 138,515,893 reduced equity.
- New share issuances of 97,496,000 increased equity.
- Other factors decreased equity by 3,704,107.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-138.52 Million | -67.71% |
| Share Issuances | $97.50 Million | +47.66% |
| Other Changes | $-3.70 Million | -1.81% |
| Total Change | $- | -17.94% |
Book Value vs Market Value Analysis
This analysis compares Verona Pharma PLC ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 34.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 39.21x to 34.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $2.19 | $86.00 | x |
| 2006-12-31 | $9.94 | $86.00 | x |
| 2007-12-31 | $7.46 | $86.00 | x |
| 2008-12-31 | $7.62 | $86.00 | x |
| 2009-12-31 | $9.44 | $86.00 | x |
| 2010-12-31 | $6.94 | $86.00 | x |
| 2011-12-31 | $8.19 | $86.00 | x |
| 2012-12-31 | $5.49 | $86.00 | x |
| 2013-12-31 | $3.99 | $86.00 | x |
| 2014-12-31 | $9.05 | $86.00 | x |
| 2015-12-31 | $3.28 | $86.00 | x |
| 2016-12-31 | $10.16 | $86.00 | x |
| 2017-12-31 | $0.98 | $86.00 | x |
| 2018-12-31 | $0.61 | $86.00 | x |
| 2019-12-31 | $3.37 | $86.00 | x |
| 2020-12-31 | $5.62 | $86.00 | x |
| 2021-12-31 | $2.50 | $86.00 | x |
| 2022-12-31 | $3.48 | $86.00 | x |
| 2023-12-31 | $3.14 | $86.00 | x |
| 2024-12-31 | $2.51 | $86.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Verona Pharma PLC ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -67.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -410.18%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 2.32x
- Recent ROE (-67.71%) is below the historical average (-36.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 2.66% | 0.00% | 0.00x | 1.01x | $-123.72K |
| 2006 | -15.60% | 0.00% | 0.00x | 1.02x | $-1.95 Million |
| 2007 | -42.14% | 0.00% | 0.00x | 1.05x | $-2.99 Million |
| 2008 | -34.33% | 0.00% | 0.00x | 1.02x | $-2.59 Million |
| 2009 | -35.68% | 0.00% | 0.00x | 1.06x | $-3.31 Million |
| 2010 | -54.85% | 0.00% | 0.00x | 1.06x | $-3.45 Million |
| 2011 | -42.46% | 0.00% | 0.00x | 1.04x | $-3.30 Million |
| 2012 | -38.27% | 0.00% | 0.00x | 1.08x | $-2.03 Million |
| 2013 | -74.04% | 0.00% | 0.00x | 1.24x | $-2.87 Million |
| 2014 | -14.06% | 0.00% | 0.00x | 1.04x | $-4.72 Million |
| 2015 | -90.56% | 0.00% | 0.00x | 1.32x | $-8.32 Million |
| 2016 | -11.80% | 0.00% | 0.00x | 1.34x | $-9.27 Million |
| 2017 | -18.99% | -1113.36% | 0.02x | 1.12x | $-31.29 Million |
| 2018 | -24.92% | -715091.63% | 0.00x | 1.18x | $-27.89 Million |
| 2019 | -68.96% | -1302385.92% | 0.00x | 1.33x | $-35.06 Million |
| 2020 | -25.77% | -2026287.20% | 0.00x | 1.10x | $-66.12 Million |
| 2021 | -27.76% | -138.92% | 0.16x | 1.26x | $-55.89 Million |
| 2022 | -24.66% | -15000.25% | 0.00x | 1.13x | $-79.88 Million |
| 2023 | -17.11% | -9311.94% | 0.00x | 1.24x | $-67.58 Million |
| 2024 | -67.71% | -410.18% | 0.07x | 2.32x | $-158.97 Million |
Industry Comparison
This section compares Verona Pharma PLC ADR's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $144,537,792
- Average return on equity (ROE) among peers: -354.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Verona Pharma PLC ADR (VRNA) | $278.27 Million | 2.66% | 1.06x | $7.31 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $117.36 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $681.00K | -3192.95% | 12.43x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $185.59 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $45.35 Million | -59.09% | 0.17x | $821.01 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $27.43 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $9.08 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.74 Billion |
About Verona Pharma PLC ADR
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more